• Explore /
  • Poster
  • / A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.

A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.

Abstract Poster

Authors

null

Kevin Kalinsky

Columbia University Medical Center, New York, NY

Kevin Kalinsky , Prabhjot Singh Mundi , Codruta Chiuzan , Melissa Kate Accordino , Meghna S. Trivedi , Joseph A. Sparano , Sun Young Oh , Amy Tiersten , Ruth O'Regan , Francisco J. Esteva , Sarika Jain , Ingrid A. Mayer , Andres Forero , Lea N. Baer , Katherine D. Crew , Dawn L. Hershman , Christos Vaklavas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT02632045

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS1112)

DOI

10.1200/JCO.2017.35.15_suppl.TPS1112

Abstract #

TPS1112

Poster Bd #

101a

Abstract Disclosures

Similar Posters

First Author: Severine Guiu Lahaye

First Author: Alicia Frances Clare Okines

First Author: Virginia F. Borges

First Author: Kelvin K H Bao